EPISODE · Mar 10, 2026 · 4 MIN
Solvonis Therapeutics CEO on SVN-114 and PTSD market opportunity
from Proactive - Interviews for investors · host Proactive Investors
Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company’s decision to select SVN-114 as the lead candidate in its post-traumatic stress disorder (PTSD) discovery programme and the opportunity the therapy could present if successfully developed. Tennyson explained that the decision followed pharmacological studies conducted by Evotec, which showed that SVN-114 provides balanced modulation across several important neurological systems. According to Tennyson, the compound influences serotonin, dopamine and noradrenaline receptors, which are all associated with mood, emotional processing and social behaviour. These systems play a significant role in the brain mechanisms involved in PTSD. He said the results were reviewed by the company’s scientific advisory committee, led by Professor David Nutt, which agreed that SVN-114 should be progressed as the lead candidate in the program. Tennyson explained that PTSD is a complex disorder involving multiple interconnected brain systems rather than a single pathway. The CEO highlighted the scale of the market opportunity, noting that PTSD affects more than 20 million people across the US, the UK and key European markets, while treatment options remain limited. Tennyson said: “If compounds like SVN-114 can demonstrate meaningful clinical benefits, then there's obviously a substantial opportunity to improve outcomes for patients and also to create value for the company and very importantly, for shareholders.” SVN-114 comes from a novel chemical series discovered by Solvonis and is supported by composition-of-matter patents, providing a strong intellectual property foundation for future development. The company is now focused on completing the remaining preclinical work required to support clinical development while pursuing non-dilutive grant funding in the UK and US. For more videos like this, visit the Proactive YouTube channel, give the video a like, subscribe to the channel and enable notifications so you never miss future updates. #SolvonisTherapeutics #AnthonyTennyson #SVN114 #PTSDTreatment #MentalHealthInnovation #DrugDevelopment #BiotechNews #Neuroscience #ClinicalDevelopment #PharmaInnovation
What this episode covers
Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company’s decision to select SVN-114 as the lead candidate in its post-traumatic stress disorder (PTSD) discovery programme and the opportunity the therapy could present if successfully developed. Tennyson explained that the decision followed pharmacological studies conducted by Evotec, which showed that SVN-114 provides balanced modulation across several important neurological systems. According to Tennyson, the compound influences serotonin, dopamine and noradrenaline receptors, which are all associated with mood, emotional processing and social behaviour. These systems play a significant role in the brain mechanisms involved in PTSD. He said the results were reviewed by the company’s scientific advisory committee, led by Professor David Nutt, which agreed that SVN-114 should be progressed as the lead candidate in the program. Tennyson explained that PTSD is a complex disorder involving multiple interconnected brain systems rather than a single pathway. The CEO highlighted the scale of the market opportunity, noting that PTSD affects more than 20 million people across the US, the UK and key European markets, while treatment options remain limited. Tennyson said: “If compounds like SVN-114 can demonstrate meaningful clinical benefits, then there's obviously a substantial opportunity to improve outcomes for patients and also to create value for the company and very importantly, for shareholders.” SVN-114 comes from a novel chemical series discovered by Solvonis and is supported by composition-of-matter patents, providing a strong intellectual property foundation for future development. The company is now focused on completing the remaining preclinical work required to support clinical development while pursuing non-dilutive grant funding in the UK and US. For more videos like this, visit the Proactive YouTube channel, give the video a like, subscribe to the channel and enable notifications so you never miss future updates. #SolvonisTherapeutics #AnthonyTennyson #SVN114 #PTSDTreatment #MentalHealthInnovation #DrugDevelopment #BiotechNews #Neuroscience #ClinicalDevelopment #PharmaInnovation
NOW PLAYING
Solvonis Therapeutics CEO on SVN-114 and PTSD market opportunity
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.